DOCSLIB.ORG

Company County City Job Title Order # Job URL Abbvie Somerset Bridgewater Director, Regulatory Affairs DE1993217

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Company County City Job Title Order # Job URL Abbvie Somerset Bridgewater Director, Regulatory Affairs DE1993217 Company County City Job Title Order # Job URL Abbvie Somerset Bridgewater Director, Regulatory Affairs DE1993217 https://nlx.jobsyn.org/0d5e15cbdfef48928c34049c1c71244e159 ABM Industries, Inc. Somerset Somerville Commercial Cleaner DE1991798 https://nlx.jobsyn.org/75ac1effb3ed474a9855e73f474897c9159 ADESA NEW JERSEY Somerset Manville Clerk, Accounting II DE2010067 https://nlx.jobsyn.org/a8a075ab3d3d4e6787c510a50d27d87d159 ADESA NEW JERSEY Somerset Manville Auction Driver DE1977166 https://nlx.jobsyn.org/8a5c10cddf8a41989cc2e785e5e9150d159 ADESA NEW JERSEY Somerset Manville Asst General Mgr I DE2009926 https://nlx.jobsyn.org/3a769bb328824c32b4102c01486f9deb159 Advance Auto Parts Somerset Manville SalesPerson DE1980621 https://nlx.jobsyn.org/b0d5442ae7fe4db4a6f709c15bcf59fc159 Advance Auto Parts Somerset Manville Retail Parts Pro DE2000529 https://nlx.jobsyn.org/935c2edd323a45098091fe7abb016d22159 Advance Auto Parts Somerset Manville Retail Parts Pro DE1980652 https://nlx.jobsyn.org/e1fe1a8d3b3b4a4e9a60a3e2b258bb51159 Advantage Solutions Somerset Hillsborough Part Time Retail Project Merchandiser DE2014897 https://nlx.jobsyn.org/2d68a74e719546dcbe9df7b80a1d6e03159 Advantage Solutions Somerset Bridgewater Part Time Retail Project Merchandiser DE2014889 https://nlx.jobsyn.org/1a736a51edf94522a9c307a4fc645c6c159 Advantage Solutions Somerset Bernardsville Part Time Retail Project Merchandiser DE2014884 https://nlx.jobsyn.org/09e75f5623c34dc7a368d6380c4eaeb2159 Air Liquide USA LLC Somerset Somerville Senior Process Development Engineer DE1977826 https://nlx.jobsyn.org/5dc9e2c0be3c45b495f92588ac64119d159 Air Liquide USA LLC Somerset Somerville Production Technician DE2010452 https://nlx.jobsyn.org/e654316ec38a4e21b7466951695fa51a159 Air Liquide USA LLC Somerset Somerville Production Technician DE2000084 https://nlx.jobsyn.org/0be6f76aca034127a64edb4aae83b503159 Akorn, Inc Somerset Somerset Senior Metrologist, Quality Control DE2000288 https://nlx.jobsyn.org/cdcef2d37a5945ed8a6df9330c61b07d159 Akorn, Inc Somerset Somerset Senior Manager, Site Technical Services Leader DE2000081 https://nlx.jobsyn.org/e146444bbd7d4c0c9b7346ae705db8a7159 Akorn, Inc Somerset Somerset Sanitization Associate I DE1976841 https://nlx.jobsyn.org/2cbb7a0acebe480a80f2e3d9f62e06cf159 Akorn, Inc Somerset Somerset Production Maintenance Supervisor DE1992003 https://nlx.jobsyn.org/b83e17a01a614ae88ffa9908d4059843159 Akorn, Inc Somerset Somerset Production Line Operator DE1977464 https://nlx.jobsyn.org/1a9cf737bb104c5b94153163efc24b21159 Akorn, Inc Somerset Somerset Microbiology Technician II- 2nd Shift DE2000118 https://nlx.jobsyn.org/1702eaa389ef402f87cf57301f6465b2159 Akorn, Inc Somerset Somerset Laboratory Data System Specialist DE1976816 https://nlx.jobsyn.org/7a53e4678a604e77b6cec6a1610f9938159 Akorn, Inc Somerset Somerset IT Service Operations Manager DE1991792 https://nlx.jobsyn.org/9037a219652f485c832163d0690c9d35159 Akorn, Inc Somerset Somerset Facility Mechanic- 3rd shift DE2000183 https://nlx.jobsyn.org/26e52ee839e44e47b8d7bbc47f2d2cbf159 Akorn, Inc Somerset Somerset Chemist I NJ DE2000337 https://nlx.jobsyn.org/0c594dc173854529a35bf9719c91dae7159 Allied Universal Somerset Somerville Security Officer Pharmaceutical DE2000768 https://nlx.jobsyn.org/995817299aa9489b9ce0bd56c518584f159 Allied Universal Somerset Somerville Security Officer Corporate Setting DE1979615 https://nlx.jobsyn.org/8eccfd686ba74b78b73669c574f8420f159 Allied Universal Somerset Somerset Security Shift Supervisor DE1979624 https://nlx.jobsyn.org/f829c5b2df174184accaa5eed3bd585b159 Allied Universal Somerset Somerset Security Officer Manufacturing DE2000749 https://nlx.jobsyn.org/7beb5a8cbe3546feb41699c430806072159 Allied Universal Somerset Somerset Security Officer Cosmetics Company DE1979693 https://nlx.jobsyn.org/cbff699d1d1940ae9416c52db14f860e159 Allied Universal Somerset Skillman Security Officer Community College DE2012357 https://nlx.jobsyn.org/50e7cd4f574241f29a44a3c45492e5a5159 Allied Universal Somerset Skillman Security Guard Shelter Home DE1979593 https://nlx.jobsyn.org/5a34862cd7344276a41b63b8e9ea3254159 Allied Universal Somerset Manville Security Shift Supervisor DE2014813 https://nlx.jobsyn.org/c5a5ab01f41a4d8d943b4362365d56ee159 Allied Universal Somerset Hillsborough Security Officer Manufacturing DE1979664 https://nlx.jobsyn.org/07c2aabb9b624a5195f0a28fd447df17159 Allied Universal Somerset Bridgewater Security Operations Center (SOC) Officer DE2012325 https://nlx.jobsyn.org/8b0d0df1bfd4498abd5df5de39272a2d159 Allied Universal Somerset Bridgewater Security Officer Corporate DE2012321 https://nlx.jobsyn.org/73b8cebe7f974d41a84cb33e776ee374159 Allied Universal Somerset Bridgewater Security Officer Corporate DE1979589 https://nlx.jobsyn.org/1d780565d36443adb1c7307509d9e860159 Allied Universal Somerset Bound Brook Security Guard Refinery DE2014809 https://nlx.jobsyn.org/cf7bb29253ae4d13a5d0355c6a2805e9159 AlphaBEST Education, Inc. Somerset Warren Group Leader- Before and/or after care program DE2010182 https://nlx.jobsyn.org/1ceae0c66c6c4157b3defe8edde625c1159 Alternatives, Inc. Somerset Raritan F/T Direct Support Professional (DSP) Floater - Somerset county DE1992686 https://nlx.jobsyn.org/b022520366104bb690e78d038db61ac9159 Amedisys Holding, LLC Somerset Somerville Hospice Bereavement Coordinator - Part Time DE2009830 https://nlx.jobsyn.org/1df60d6665244306a9fb4c6e78576521159 Americold Logistics, LLC Somerset Bridgewater LTO Warehouse Worker DE2000261 https://nlx.jobsyn.org/67a52457cf4f40d4acdae7fd50015099159 Amneal Pharmaceuticals LLC (J0P) Somerset Somerville Scientist III, Quality Control DE2010761 https://nlx.jobsyn.org/420ac7f733e646e8ab534a847ed23304159 Amneal Pharmaceuticals LLC (J0P) Somerset Somerville Scientist I, Quality Control DE2010872 https://nlx.jobsyn.org/cb860e188bc24532bf1426ea9fcb6a71159 Amneal Pharmaceuticals LLC (J0P) Somerset Somerville Scientist I, Quality Control DE2010811 https://nlx.jobsyn.org/7763935430284e33b71e66c8067942c9159 Amneal Pharmaceuticals LLC (J0P) Somerset Somerville QA Systems (Caliber) Coordinator DE2010710 https://nlx.jobsyn.org/73947ddfbd8b4f26a55a240ada05a5de159 Amneal Pharmaceuticals LLC (J0P) Somerset Somerville NOI Investigations Specialist DE2010639 https://nlx.jobsyn.org/0c3c166d71e6484f81a73586dbe4c0ba159 Amneal Pharmaceuticals LLC (J0P) Somerset Somerville Mixing Operator III - 2nd Shift DE1983636 https://nlx.jobsyn.org/ad7c44cf644446ecbf7ca8a97feb4bdd159 Aon Corporation Somerset Somerset Time Away & Life Solutions Consultant DE2010813 https://nlx.jobsyn.org/0eb1e919187d49aeb01817ca86aeb8cf159 Aon Corporation Somerset Somerset Health Solutions Vice President DE1977619 https://nlx.jobsyn.org/12d0e09af6c64151a277971a6f0df4a1159 Apex Systems, Inc Somerset Warren Research Associate - Process Analytics (CAR-T) (1116177) DE1983436 https://nlx.jobsyn.org/87143c118cb747db8a8da64a6d5173b5159 Apex Systems, Inc Somerset Warren Research Associate - Molecular (CAR-T) (1116539) DE2010953 https://nlx.jobsyn.org/f4eb3276f4a841aab8a1675c46afad2d159 Apex Systems, Inc Somerset Basking Ridge Business / Financial Analyst - II (1115679) DE2010853 https://nlx.jobsyn.org/4b882189d4d543d0ad4f5088f0e04c92159 Apex Systems, Inc Somerset Basking Ridge Accountant - III (1113143) DE2010903 https://nlx.jobsyn.org/cb04cdaa81ec4aab904636124539d370159 Aromatic Technologies, Inc., d/b/a Agilex Fragrances Somerset Somerset Utility Operator - 1st Shift DE2009894 https://nlx.jobsyn.org/72fbc1c9c2dd4d54b1a48afb47c87c56159 Ashland, LLC Somerset Bridgewater Product Regulatory Specialist, Personal and Home Care DE1977400 https://nlx.jobsyn.org/f2ae5b7be9af4236ac1d866578072d21159 Ashland, LLC Somerset Bridgewater Mass Spectrometry Chemist DE1991955 https://nlx.jobsyn.org/23cee1e9851349d7858cb9c62a201b6a159 Ashland, LLC Somerset Bridgewater Global Marketing Manager, Home Care DE1999981 https://nlx.jobsyn.org/1f3893a3d06b420da5d8e70cd121f6b4159 AT&T Somerset Bridgewater Bilingual Spanish Sales Representative - Consumer Acquisition DE2000748 https://nlx.jobsyn.org/6f9a20473b2b492d96efd3734da241f8159 AT&T Somerset Bedminster Technical Sales Consultant 4 DE1972605 https://nlx.jobsyn.org/b3d0ed1a4cfe49f6a13be466d55596c0159 AT&T Somerset Bedminster Software Engineer 2 DE1983915 https://nlx.jobsyn.org/4ce5855831f141c5a034e75f54bf05b2159 AT&T Somerset Bedminster Senior Software Engineer DE1980338 https://nlx.jobsyn.org/9a86ec58aa634ea99d2ce8a1ef328dcd159 AT&T Somerset Bedminster Senior Manager, Corporate Retail Real Estate DE2000790 https://nlx.jobsyn.org/e66c1268604f402780ae6d35d05cdbc8159 AT&T Somerset Bedminster Sales Executive Acquisition DE1981363 https://nlx.jobsyn.org/1fbe669a7ba44e29be1d642137353834159 AT&T Somerset Bedminster Principal-Software Engineer DE1980459 https://nlx.jobsyn.org/360231ef14c04b778374df17afacab8e159 AT&T Somerset Bedminster Client Solutions Executive 4 DE2014778 https://nlx.jobsyn.org/6169d03f5ec9484e86cc47b67cf0be8e159 AT&T Somerset Bedminster Bilingual Spanish Sales Representative - Consumer Acquisition DE2000766 https://nlx.jobsyn.org/a01086ad614846d1a5255340a417504c159 Atalian Global Services Somerset Warren Full-Time Evening Cleaners (Operations) DE2000839 https://nlx.jobsyn.org/934104b3b523401eacf2d15c661deb82159 Avantor, Inc. Somerset Bridgewater Strategic Program Manager, New Product Introductions DE1979645 https://nlx.jobsyn.org/6420aac1db9e47189223c637c3f04f17159 Avantor, Inc. Somerset Bridgewater Senior Strategic Program Manager, New Product Introductions DE1979665 https://nlx.jobsyn.org/dc0727a063524e61a7484d9222659fe8159 Barnes
Load more

Recommended publications
  • Symbols Alexian Brothers Health System Index to Nov P
    Volume 19, Index December 2014 Symbols Alexian Brothers Health System Index to Nov p. 2 Health Care M&A News 1-800-CONTACTS Feb p. 18 A&L Goodbody Apr p. 16, July p. 16 All Care Home Health, LLC Feb p. 17 Each company and orga- A Allergan Inc. Feb p. 10, May p. 1, nization discussed in Health May p. 19, Jun p. 15, July p. 3, Care M&A News, from Janu- Abbott Labs July p. 3, Aug p. 17, July p. 10, Sept p. 16, Oct p. 3, ary through December 2014, Dec p. 4 Nov p. 1, Dec p. 4, Dec p. 16, is listed alphabetically here. AbbVie Inc. July p. 3, July p. 16, Dec p. 19 References are typically to Aug p. 9, Oct p. 2, Oct p. 16, Allscripts Feb p. 2, Apr p. 10 the first occurrence of the Nov p. 19, Dec p. 2 AllSpire Health Partners Nov p. 2 company’s or organiza- ABL, Inc. Aug p. 18 All Staffing Services Jan p. 17 tion’s name in the pertinent Acadia Healthcare Company Feb p. 16, Almost Family, Inc. Apr p. 16 issue; further discussion July p. 17, Oct p. 17, Nov p. 17 ALN Medical Management, LLC may follow later in the text Accelera Innovations, Inc. Jan p. 17 Accelrys, Inc. Jan p. 15 Feb p. 8 but is not indicated here. AccessClosure, Inc. May p. 15 Alta Partners Jun p. 16 Achillion Pharmaceuticals July p. 17 Altos Solutions, Inc. Jun p. 15 References are sorted by Actavis (Foshan) Pharmaceuticals Co.
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Healthcare & Life Sciences Group
    HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry.
    [Show full text]
  • Stamford Therapeutics Consortium Consortiapedia.Fastercures.Org
    Stamford Therapeutics Consortium consortiapedia.fastercures.org Stamford Therapeutics Consortium consortiapedia.fastercures.org/consortia/stamford-therapeutics-consortium/ Research Areas At a Glance Status: Active Consortium Tool Development Year Launched: 1994 Clinical Trial Initiating Organization: Dr. Paul Dalgin Data-Sharing Enabler Initiator Type: Industry Location: North America DevelopmentProduct Drugs Abstract Stamford Therapeutics Consortium (STC) is a privately owned and operated clinical research site specializing in phase II, III, and IV clinical trials for the pharmaceutical and biotechnology industries. STC has a strong working relationship with a cardiology group, a large multispecialty medical practice, and a team of physicians who serve as sub-investigators for many of its clinical trials. STC maintains a significant presence in research for the treatment of osteoarthritis and rheumatoid arthritis, while continuing to expand its research into new therapeutic areas. Year after year STC's list of specialties grows to accommodate a growing demand and new innovations in healthcare. With over 15 years of clinical trials operations, STC has conducted more than 350 national and multi-national clinical trials. Mission The company’s sole mission is to conduct the highest quality clinical trials so that new, safe, and effective medications can be developed, researched, and approved for a variety of indications and diseases. Stamford Therapeutics Consortium - consortiapedia.fastercures.org Page 1/4 Stamford Therapeutics Consortium consortiapedia.fastercures.org Consortium History The site was launched in 1994 and has contributed to clinical trials research ever since. Structure & Governance The consortium is governed by their president, medical director, founder, and clinical research coordinators. Patent Engagement STC actively recruits patients from all over Fairfield County, CT and Westchester County, NY.
    [Show full text]
  • Bristol-Myers Squibb Company [email protected]
    UNITED STATES SECURITIES A ND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE March 1, 2019 Lisa A. Atkins Bristol-Myers Squibb Company [email protected] Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 Dear Ms. Atkins: This letter is in response to your correspondence dated December 21, 2018 concerning the shareholder proposal (the “Proposal”) submitted to Bristol-Myers Squibb Company (the “Company”) by People for the Ethical Treatment of Animals (the “Proponent”) for inclusion in the Company’s proxy materials for its upcoming annual meeting of security holders. We also have received correspondence from the Proponent dated January 3, 2019. Copies of all of the correspondence on which this response is based will be made available on our website at http://www.sec.gov/divisions/corpfin/ cf-noaction/14a-8.shtml. For your reference, a brief discussion of the Division’s informal procedures regarding shareholder proposals is also available at the same website address. Sincerely, M. Hughes Bates Special Counsel Enclosure cc: Jared Goodman PETA Foundation [email protected] March 1, 2019 Response of the Office of Chief Counsel Division of Corporation Finance Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 The Proposal asks the board to implement a policy that it will not fund, conduct or commission use of the “Forced Swim Test.” There appears to be some basis for your view that the Company may exclude the Proposal under rule 14a-8(i)(7), as relating to the Company’s ordinary business operations. In our view, the Proposal micromanages the Company by seeking to impose specific methods for implementing complex policies.
    [Show full text]
  • Investor Presentation March 19, 2019
    Transaction Update INVESTOR PRESENTATION MARCH 19, 2019 1 Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), on February 1, 2019, Bristol-Myers Squibb filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended on February 1, 2019 and February 20, 2019, containing a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol- Myers Squibb. The registration statement was declared effective by the SEC on February 22, 2019, and Bristol-Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019. INVESTORS AND SECURITY HOLDERS OF BRISTOL-MYERS SQUIBB AND CELGENE ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by Bristol-Myers Squibb or Celgene through the website maintained by the SEC at http://www.sec.gov.
    [Show full text]
  • Healthcare & Life Sciences Industry Update
    Healthcare & Life Sciences Industry Update August 2011 Member FINRA/SIPC www.harriswilliams.com What We’ve Been Reading August 2011 • The biggest story from inside the Beltway over the last month was the battle and eventual deal to raise the U.S. debt ceiling to avoid an impending August 2nd default. The Budget Control Act of 2011 will raise the debt ceiling by $2.1-$2.4 trillion, while reducing spending by approximately $2.1 trillion over the next decade. In an interesting post-deal analysis, Michael Hiltzik of the Los Angeles Times notes that despite the protracted negotiations over a broad spectrum of cost-cutting measures, healthcare was not raised as a primary issue. Some have found this especially concerning, considering the outsized portion of the Federal Budget currently allocated to healthcare spending, which is forecast to rise in the coming years. A recent article in The Economist, entitled “Looking to Uncle Sam” makes this point and goes further to suggest that Centers for Medicare & Medicaid Services (CMS) actuaries may be underestimating future increases in Medicare and Medicaid spending. • One potential reason CMS actuaries may be underestimating the future costs of Medicare and Medicaid relates to healthcare reform’s effect on employee benefits, and specifically, the 2014 switch to subsidized exchange policies. A recent report by McKinsey & Company estimates that approximately 30% of employers will stop offering employer- sponsored insurance (ESI) when this switch is made, as opposed to the 7% estimated by the Congressional Budget Office. An ESI exodus of this magnitude could cause substantial strain on an already robust government healthcare budget.
    [Show full text]
  • Download Agenda
    Break Through Affordability Barriers to Streamline Operational Complexities, Enhance Patient Access and Optimize Stakeholder Collaboration August 17-19, 2021 Elevated Insights Shared From Top Leaders Across the Access and Affordability Landscape Bill Goodson, Savaria B. Harris, Director, Senior Counsel, Patient Assistance, Regulatory Law, EISAI JOHNSON & JOHNSON Tyler Scheid, Debra Autry, Senior Policy Analyst, Medication Access AMERICAN MEDICAL Coordinator, ASSOCIATION HEALTH ALLIANCE FOR THE UNINSURED Viveca Parker, Assistant US Attorney, PLUS! Perspectives from Sanofi, Mallinckrodt DEPARTMENT OF JUSTICE Pharmaceuticals, Acceleron Pharma Inc., and more! INFORMACONNECT.COM/PAP #PAP2021 ABOUT THIS EVENT Now in its 22nd year, Informa Connect’s Patient Assistance and Access Programs convenes leaders from across the assistance, access and affordability field to benchmark on PAP industry standards and break through affordability barriers to streamline operational complexities, enhance patient access and optimize stakeholder collaboration. % 4% Bio/Pharma 57% AUDIENCE SNAPSHOT 5 3% Non-Profit/Foundation 21% 2021 ADVISORY 10% Consulting 10% COMMITTEE: March 2021 % Delegation Breakdown: 21% 57 Health Plan/System 5% Pharmacy/PBMs 4% A sincere thank you to the Hospital/Medical Center/Clinic 3% Advisory Committee Members for their support and guidance in developing the robust program agenda aimed at BENCHMARKING DATA addressing industry’s most pressing challenges. The Top 3 Biggest of surveyed individuals changed the % course of the programs they
    [Show full text]
  • Greater Raritan Labor Insight Analysis
    Greater Raritan 90-Day Labor Insight Analysis • Somerset County • Hunterdon County Greater Raritan Cities With The Most Listings Last 90 days (Nov. 7, 2019 - Feb. 4, 2020) * Due to data coding errors, all Heavy and Tractor-Trailer Truck Driver occupations have been suppressed Bridgewater, NJ 3,368 Franklin, NJ 2,407 Bernards, NJ 2,264 Bound Brook, NJ 1,091 Flemington, NJ 930 Somerville, NJ 865 Warren, NJ 811 Raritan, NJ 706 Bedminster, NJ 621 Readington, NJ 472 Hillsborough, NJ 470 Montgomery, NJ 316 Peapack, NJ 274 Watchung, NJ 261 Clinton, NJ 236 North Plainfield, NJ 187 Lebanon, NJ 172 Bernardsville, NJ 113 Manville, NJ 103 Green Brook, NJ 94 Gladstone, NJ 73 0 1,000 2,000 3,000 4,000 • Source: Burning Glass Technologies Inc., Labor Insight Prepared by New Jersey Department of Labor & Workforce Development – February, 2020 Greater Raritan Industries (4 digit NAICS) With The Most Listings Last 90 days (Nov. 7, 2019 - Feb. 4, 2020) * Due to data coding errors, all Heavy and Tractor-Trailer Truck Driver occupations have been suppressed Pharmaceutical and Medicine Manufacturing 1,206 Wired Telecommunications Carriers 656 General Medical and Surgical Hospitals 584 Insurance Carriers 446 Restaurants and Other Eating Places 297 Business Support Services 273 Scientific Research and Development… 256 Depository Credit Intermediation 227 Health and Personal Care Stores 204 Employment Services 199 Computer Systems Design and Related… 193 Offices of Physicians 178 Building Material and Supplies Dealers 156 Clothing Stores 151 Management, Scientific, and Technical… 142 Traveler Accommodation 139 Software Publishers 129 Architectural, Engineering, and Related… 114 Accounting, Tax Preparation, Bookkeeping,… 105 Investigation and Security Services 103 Home Health Care Services 99 0 500 1,000 1,500 • Source: Burning Glass Technologies Inc., Labor Insight Prepared by New Jersey Department of Labor & Workforce Development – February, 2020 Greater Raritan Employers With The Most Listings Last 90 days (Nov.
    [Show full text]
  • Emmett Cunningham, Jr., M.D., Ph.D., M.P.H
    2019 - Emmett Cunningham, Jr., M.D., Ph.D., M.P.H. Senior Managing Director Blackstone Life Sciences HEATHEGY TEAM CRAIG SIMAK CRAIG SIMAK DANIELLE SILVA MAUREEN LINNEMANN 1200 OIS@AAO 24 Meetings > 1,150 1000 ~ 13,500 Attendees 800 OIS@ASCRS 600 > 650 400 OIS@ASRS 200 > 300 0 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Registrants 3% 10% OIS@AAO 2019 ( > 1,150) 8% Academia, Government, or Association 41% Adviser, Consultant, or Service Provider Finance/Investment Firm Large Multi-National Corporation Physician/Healthcare Provider 25% Press/Media Start-up/Emerging Growth Company 3% 25 Countries 10% 32 US States Record Number of CDER NME NDA/BLA Approvals in 2018 70 BLA 59 60 NDA 50 45 46 Number 39 41 of 40 35 36 Drugs 30 30 30 27 27 24 26 22 24 21 20 21 22 20 17 18 10 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Source: FDA 1998 - 2018 High Innovation Record Number of • 31 (53%) Orphan CDER NME NDA/BLA Approvals in 2018 • 26 (44%) Priority Review • 16 (27%) Fast Track • 12 (20%) Break Through Designation 59 • 18 (30%) Oncology • 1 (0%) Ophthalmology Cenegermin-bkbj Ophthalmic Solution, (OXERVATE®) Ophthalmic Drugs Streamlined Reporting of Ophthalmology Clinical Group CDER As of January, 2018 Ophthalmology Clinical Group Reported Directly & Independently to Deputy Director Office of New Drugs Peter Stein, MD Five Additional Office of Offices of Drug Antimicrobial Evaluation (ODEs) Products Division of Division of Division of Transplant and Anti-Infective Anti-Viral Ophthalmology Products Products Dr.
    [Show full text]
  • Liver Forum 8 Final Participant List
    Liver Forum 8 Final Participant List Manal Abdelmalek, MD, MPH WG P Merav Baz Hecht * Roberto Calle, MD P Duke University School of Medicine Novo Nordisk Inc. Foundation for the National Institutes of Health Jean-Louis Abitbol, MD, MSC* Pierre Bedossa, MD, PhD Inventiva Pharma University of Paris Diderot Bjorn Carlsson, MD, PhD AstraZeneca Juan Gonzalez Abraldes, MD, MMSc* Cynthia Behling, MD, PhD* University of Alberta University of California, San Diego Santos Carvajal, PhD* Pfizer Inc. Nathalie Adda, MD Martin Benson, BSc, PhD* Enanta Pharmaceuticals, Inc. ICON Clinical Research Laurent Castera, MD, PhD Hôpital Beaujon Guruprasad Aithal, BSc, MBBS, MD, Jerome Bernard, PhD FRCP, PhD DIAFIR SA Naga Chalasani, MD SC WG P University of Nottingham Indiana University School of Medicine Mark Berner-Hansen, MD, DMSc Peter Alfinito, PhD Zealand Pharma Jean Chan, MD WG P Covance Conatus Pharmaceuticals, Inc. Annalisa Berzigotti, MD, PhD SC Alina Allen, MD* Inselspital, University of Bern Edgar Charles, MD, MSc Mayo Clinic Bristol-Myers Squibb Jaime Bosch, MD, PhD, FRCP, Ryan Anderson, MS FAASLD Bentley Cheatham, PhD* Forum for Collaborative Research Inselspital, University of Bern Avolynt, Inc Quentin Anstee, BSc, MBBS, PhD, Pol Boudes, MD, PhD Ying Chen, MD* FRCP P CymaBay Therapeutics, Inc. China Food and Drug Administration Newcastle University Medical School Sherif Boulos, BSc(Hons), MSc, PhD Annie Chen, MD, MPH* Anuli Anyanwu-Ofili* Resonance Health Nimbus Therapeutics Janssen Johan Brag, MS, JD Cheronda Cherry-France, MSN, Puneet Arora,
    [Show full text]
  • Validation of Serum Neurofilament Light Chain As a Biomarker of Parkinson’S Disease Progression
    bioRxiv preprint doi: https://doi.org/10.1101/762237; this version posted December 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression Brit Mollenhauer1,2†, MD; Mohammed Dakna1, PhD; Tzu-Ying Liu3, PhD; Douglas Galasko4, MD; Tatiana Foroud5, PhD; Henrik Zetterberg6,7,8,9, MD; Sebastian Schade1, MD; Roland G. Gera10, MSc Wenting Wang3, PhD, Feng Gao3, PhD; Niels Kruse11, PhD; Mark Frasier12, PhD; Lana M. Chahine13, MD; Christopher S. Coffey,14 PhD; Andrew B. Singleton,15 PhD; Tanya Simuni,16 MD; Daniel Weintraub,17 MD; John Seibyl,18 MD; Arthur W. Toga,19 PhD; Caroline M. Tanner,20 MD, PhD; Karl Kieburtz,21 MD; Kenneth Marek12,18, MD; Andrew Siderowf17, MD; Jesse M. Cedarbaum22 MD; Samantha J. Hutten12, PhD; Claudia Trenkwalder2*, MD; Danielle Graham23*, PhD *both last authors contributed equally 1 Department of Neurology, University Medical Center Goettingen, Germany: [email protected]; [email protected]; [email protected] 2 Paracelsus-Elena Klinik, Kassel, Germany, [email protected] 3 Biostatistics, Biogen, Cambridge MA, USA; [email protected]; [email protected]; [email protected] 4 Department of Neurosciences, University of California, San Diego, San Diego, CA, USA: [email protected] 5 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA; [email protected] 6 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
    [Show full text]